Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer

BACKGROUND: Several recent randomized controlled trials (RCTs) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) have demonstrated significant improvements in progression-free survival (PFS); however, few have reported improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Tremblay, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942170/
https://www.ncbi.nlm.nih.gov/pubmed/29765247
http://dx.doi.org/10.2147/BCTT.S162841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942170/
https://www.ncbi.nlm.nih.gov/pubmed/29765247
http://dx.doi.org/10.2147/BCTT.S162841

Ejemplares similares